The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Effect of Varying Doses of Epicutaneous Immunotherapy vs Placebo on Reaction to Peanut Protein Exposure Among Patients With Peanut Sensitivity: A Randomized Clinical Trial
Open accessAbstract
Importance: Epicutaneous immunotherapy may have potential for treating peanut allergy but has been assessed only in preclinical and early human trials. Objective: To determine the optimal dose, adverse events (AEs), and efficacy of a peanut patch for peanut allergy treatment. Design, Setting, and Participants: Phase 2b double-blind, placebo-controlled, dose-ranging trial of a peanut patch in peanut-allergic patients (6-55 years) from 22 centers, with a 2-year, open-label extension (July 31, 2012-July 31, 2014; extension completed September 29, 2016). Patients (n = 221) had peanut sensitivity and positive double-blind, placebo-controlled food challenges to an eliciting dose of 300 mg or less of peanut protein. Interventions: Randomly assigned patients (1:1:1:1) received an epicutaneous peanut patch containing 50 μg (n = 53), 100 μg (n = 56), or 250 μg (n = 56) of peanut protein or a placebo patch (n = 56). Following daily patch application for 12 months, patients underwent a double-blind, placebo-controlled food challenge to establish changes in eliciting dose. Main Outcomes and Measures: The primary efficacy end point was percentage of treatment responders (eliciting dose: ≥10-times increase and/or reaching ≥1000 mg of peanut protein) in each group vs placebo patch after 12 months. Secondary end points included percentage of responders by age strata and treatment-emergent adverse events (TEAEs). Results: Of 221 patients randomized (median age, 11 years [quartile 1, quartile 3: 8, 16]; 37.6% female), 93.7% completed the trial. A significant absolute difference in response rates was observed at month 12 between the 250-μg (n = 28; 50.0%) and placebo (n = 14; 25.0%) patches (difference, 25.0%; 95% CI, 7.7%-42.3%; P = .01). No significant difference was seen between the placebo patch vs the 100-μg patch. Because of statistical testing hierarchical rules, the 50-μg patch was not compared with placebo. Interaction by age group was only significant for the 250-μg patch (P = .04). In the 6- to 11-year stratum, the response rate difference between the 250-μg (n = 15; 53.6%) and placebo (n = 6; 19.4%) patches was 34.2% (95% CI, 11.1%-57.3%; P = .008); adolescents/adults showed no difference between the 250-μg (n = 13; 46.4%) and placebo (n = 8; 32.0%) patches: 14.4% (95% CI, -11.6% to 40.4%; P = .40). No dose-related serious AEs were observed. The percentage of patients with 1 or more TEAEs (largely local skin reactions) was similar across all groups in year 1: 50-μg patch = 100%, 100-μg patch = 98.2%, 250-μg patch = 100%, and placebo patch = 92.9%. The overall median adherence was 97.6% after 1 year; the dropout rate for treatment-related AEs was 0.9%. Conclusions and Relevance: In this dose-ranging trial of peanut-allergic patients, the 250-μg peanut patch resulted in significant treatment response vs placebo patch following 12 months of therapy. These findings warrant a phase 3 trial. Trial Registration: clinicaltrials.gov Identifier: NCT01675882.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Food allergy: A practice parameter update—2014
Sampson, H. A., Aceves, S., Bock, S. A., James, J., Jones, S., Lang, D., Nadeau, K., Nowak-Wegrzyn, A., Oppenheimer, J., Perry, T. T., et al. (2014) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2014.05.013 · Cited by 845
Self-citationFilaggrin in atopic dermatitis
O'Regan, G. M., Sandilands, A., McLean, W. H. I., & Irvine, A. D. (2008) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2008.08.002 · Cited by 350
Cited by
Sicherer, S. H., & Sampson, H. A. (2018) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2017.11.003 · Cited by 1,628
Self-citationAnvari, S., Miller, J., Yeh, C.-Y., & Davis, C. M. (2019) · Clinical Reviews in Allergy & Immunology · doi:10.1007/s12016-018-8710-3 · Cited by 399
Fleischer, D. M., Greenhawt, M., Sussman, G., Bégin, P., Nowak-Wegrzyn, A., Petroni, D., Beyer, K., Brown-Whitehorn, T., Hebert, J., Hourihane, J. O., et al. (2019) · JAMA · doi:10.1001/jama.2019.1113 · Cited by 276
Self-citationFood Allergy from Infancy Through Adulthood
Sicherer, S. H., Warren, C. M., Dant, C., Gupta, R. S., & Nadeau, K. C. (2020) · The Journal of Allergy and Clinical Immunology: In Practice · doi:10.1016/j.jaip.2020.02.010 · Cited by 201
Self-citationMechanisms of Allergen-Specific Immunotherapy and Allergen Tolerance
Kucuksezer, U. C., Ozdemir, C., Cevhertas, L., Ogulur, I., Akdis, M., & Akdis, C. A. (2020) · Allergology International · doi:10.1016/j.alit.2020.08.002 · Cited by 173
Metadata
- Authors
- Sampson, H. A., Shreffler, W. G., Yang, W. H., Sussman, G. L., Brown-Whitehorn, T. F., Nadeau, K. C., Cheema, A. S., Leonard, S. A., Pongracic, J. A., Sauvage-Delebarre, C., Assa’ad, A. H., de Blay, F., Bird, J. A., Tilles, S. A., Boralevi, F., Bourrier, T., Hébert, J., Green, T. D., Gerth van Wijk, R., Knulst, A. C., Kanny, G., Schneider, L. C., Kowalski, M. L., & Dupont, C.
- Venue
- JAMA
- Publisher
- American Medical Association (AMA)
- Published
- 2017-11-14
- Volume
- 318
- Issue
- 18
- Pages
- 1798
- ISSN
- 0002-9955 (ISSN-L)
- 0098-7484
- OpenAlex
- W2768781972
- Cited by
- 218
- References
- 2
- FWCI
- 20.99
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Effect of Varying Doses of Epicutaneous Immunotherapy vs Placebo on Reaction to Peanut Protein Exposure Among Patients With Peanut Sensitivity: A Randomized Clinical Trial. https://app.cochat.ai/papers/10.1001/jama.2017.16591
- The paper
- Sampson, H. A., Shreffler, W. G., Yang, W. H., Sussman, G. L., Brown-Whitehorn, T. F., Nadeau, K. C., Cheema, A. S., Leonard, S. A., Pongracic, J. A., Sauvage-Delebarre, C., Assa’ad, A. H., de Blay, F., Bird, J. A., Tilles, S. A., Boralevi, F., Bourrier, T., Hébert, J., Green, T. D., Gerth van Wijk, R., . . . Dupont, C. (2017). Effect of Varying Doses of Epicutaneous Immunotherapy vs Placebo on Reaction to Peanut Protein Exposure Among Patients With Peanut Sensitivity: A Randomized Clinical Trial. JAMA. https://doi.org/10.1001/jama.2017.16591
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.